Non-toxic vehicle to solubilize, deliver, and obtain biological activity of steroid hormones at cell, tissue, and organ targets, in vitro and in vivo
a steroid hormone and biological activity technology, applied in the field of animal models, can solve the problems of inability to dissolve steroid hormones in solvents, hampered use and application of steroid hormones in hormone therapy, and use of peg alon
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
[0054]A non-toxic vehicle for administration of androstene hormones according to embodiments of the present invention was prepared from a first solution and a second solution. The first solution, comprising liposomal formulation, was placed in PEG 300 to a concentration of 5% and heated in a sonicating water bath to about 45° C. The second solution, comprising a selected hormone (one or more of 5Δ-androsten-3β, 17α-diol, 5Δ-androsten-3β, 17β-diol, or 5Δ-androsten-3β,7β,17β-triol), was placed in PEG 300 and heated in a sonicating water bath to about 45° C. The first and second solutions were then combine and stirred until dissolved.
[0055]Biological function was tested in 293T cells, which is a human embryonic cell line transformed with Large T antigen or SV40. This hypotriploid (polyploid) cell line is particularly useful in such transformation studies and has very distinct phenotypes when grown. All androstene hormone treatment applications were at concentrations of 25 μM.
[0056]FIG....
example 2
[0066]Hormone dependent, noninvasive, epithelial phenotype (ER / PR positive MCF-7 breast cancer cells) and hormone independent, invasive, mesenchymal phenotype (ER / PR negative MDA-MB-231 breast cancer cell) cell suspensions were acquired and prepared in complete medium (DMEM / F12, 10% FBS, 1% penicillin / streptomycin (Gibco)). Cellular concentration was adjusted to 2×105 cells / mL.
[0067]Androstene hormone solutions according to embodiments of the present invention were prepared from a first solution and a second solution. For the first solution, 3.0 mg of β-AED or β-AET was added to warm PEG 300 to prepare 50 mM stock. For the second solution, 10 μL of LIPOFECTAMINE (3:1 DOSPA: DOPE) was introduced to 100 μL of PEG 300, mixed, and incubated in a water bath at 42° C. for 30 min. The first and second solutions were then mixed in a sonicator water bath at 42° C. for 1 hr. The final concentration was 50 mM β-AED (or AET, as used).
[0068]A β-estradiol solution was also prepared by adding 2.7 ...
PUM
| Property | Measurement | Unit |
|---|---|---|
| humidity | aaaaa | aaaaa |
| humidity | aaaaa | aaaaa |
| concentration | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 


